All In MedTech

FDA Clearance Tracker · P000029

DEFLUX INJECTABLE GEL

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2001 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 24, 2001

Approved

Time to decision

440 days

Received Jul 11, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P000029
Device name
DEFLUX INJECTABLE GEL
Applicant location
Santa Barbara, CA
Received
Jul 11, 2000
Decided
Sep 24, 2001
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
93 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR DEFLUX INJECTABLE GEL. THE DEVICE IS INDICATED FOR TREATMENT OF CHILDREN WITH VESICOURETERAL REFLUX (VUR) GRADES II-IV.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LNM. The earliest in FDA's data is P900030, decided Sep 30, 1993.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Palette Life Sciences

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.